Seeking Alpha

Bhavneesh Sharma

 
View as an RSS Feed
View Bhavneesh Sharma's Comments BY TICKER:
Latest  |  Highest rated
  • Cel-Sci's Multikine - Potential 21st Century Superdrug [View article]
    Cancer vaccines will hardly find use as sole therapies. Maybe they will be used in combination with drugs like anti-PD1 or anti CTLA4 drugs. Wait till a antiPD4 drug finds use in head and neck cancer. Short term, this may run up to low single digits though.
    Mar 13 09:15 PM | Likes Like |Link to Comment
  • Ocera Therapeutics: An Undervalued Biopharma Company With A Lot Of Upside [View article]
    my fund feed is at @VasudaBioFund
    Mar 9 11:57 AM | Likes Like |Link to Comment
  • Ocera Therapeutics: An Undervalued Biopharma Company With A Lot Of Upside [View article]
    @Henry Su: Thanks for the stats. Rifaximin is combined with lactulose in acute treatment of HE. Lactulose is difficult to administer in a drowsy patient. Usually, these patients will need a nasogastric tube inserted to administer lactulose which increases the risk of aspiration. Lactulose can be given rectally but it is labor intensive for nurses (and messy). Also, it causes diarrhea (which is used as the end point when we start to decrease the dosing frequency) and is messy for the nursing to manage.
    An iv drug even if more expensive will be easily adopted in this condition if it shows a clinical advantage over standard therapy. For example, iv N-acetalcysteine (mucomyst), though more expensive, is now used more frequently than PO form in acetaminophen overdose (PO form is 17 doses; very difficult to administer as these patients may be drowsy or nauseous). I don't expect any insurance approval issues if it reduces the ICU and hospital stay.
    Feb 26 02:54 PM | Likes Like |Link to Comment
  • Ocera Therapeutics: An Undervalued Biopharma Company With A Lot Of Upside [View article]
    @barry55: The symbol in the first sentence is correct.
    Feb 26 02:47 PM | Likes Like |Link to Comment
COMMENTS STATS
4 Comments
0 Likes